

شماره: ۶۵۵/۳۰۷۹۲
تاریخ: ۱۴۰۰/۰۶/۰۷
پیوست: دارد


جمهوری اسلامی ایران
وزارت بهداشت، درمان
و آموزش پزشکی


سازمان غذا و دارو
IFDA

معاون محترم غذا و داروی دانشگاه های علوم پزشکی و خدمات بهداشتی درمانی سراسر کشور

موضوع: هشدار سازمان جهانی بهداشت در خصوص واکسن تقلبی کووید ۱۹ با نام تجاری Covishield- معاونین غذا و داروی سراسر کشور

با سلام؛

با احترام، عطف به نامه شماره ۱/۳۱۸۰۳ مورخ ۱۴۰۰/۶/۱ نماینده محترم سازمان جهانی بهداشت، در خصوص هشدار آن سازمان در خصوص واکسن تقلبی کووید ۱۹ با نام تجاری Covishield به آگاهی می رساند، مطابق اعلام سازمان جهانی بهداشت، نمونه هایی از واکسن تقلبی کووید ۱۹ با نام تجاری Covishield در منطقه آسیای جنوب شرقی و آفریقایی سازمان جهانی بهداشت شناسایی و به آن سازمان گزارش شده که مشخصات آن مطابق جدول و تصویر زیر می باشد.



تهران روبروی درب اصلی دانشگاه تهران، خیابان فخر رازی، نبش خیابان شهید وحید نظری، سازمان غذا و دارو

تلفن: ۹-۶۶۴۶۷۲۶۸-۹ شماره: ۶۶۴۶۹۱۲۲ کد پستی: ۱۳۱۴۷۱۵۳۱۱

www.fda.gov.ir

شماره: ۶۵۵/۳۰۷۹۲
تاریخ: ۱۴۰۰/۰۶/۰۷
پیوست: دارد



Table 1: Products subject of WHO Medical Product Alert N°5/2021

Product name	COVISHIELD, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)	
Stated manufacturer	Serum Institute of India Pvt. Ltd.	
Stated dose	5ml (10 doses)	2ml (4 doses)
Batch	4121Z040	Not stated
Mfg. date	Not stated	Not stated
Exp. date	10.08.2021	Not stated
Packaging language	English	English
Identified in	Uganda	India

با عنایت به احتمال وجود واکسن های تقلبی در بازار سیاه دارویی کشور، ضمن تاکید مجدد بر لزوم کنترل اصالت همه فرآورده های سلامت محور در سامانه ردیابی و رهگیری اصالت (TTAC)، خواهشمنداست دستور فرمایید، مراتب به همه مراکز دارویی، درمانی و بهداشتی تحت پوشش آن معاونت محترم اطلاع رسانی شود.

دکتر محمدرضا شانه ساز
معاون وزیر و رئیس سازمان غذا و دارو

تهران روبروی درب اصلی دانشگاه تهران، خیابان فخر رازی، نبش خیابان شهید وحید نظری، سازمان غذا و دارو

تلفن: ۹-۶۶۴۶۷۲۶۸-۶۶۴۶۹۱۲۲ نمابر: ۶۶۴۶۹۱۲۲ کد پستی: ۱۳۱۴۷۱۵۳۱۱

www.fda.gov.ir



Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine

Falsified COVISHIELD vaccine identified in the WHO regions of Africa and South- East Asia

16 August 2021 | Medical product alert | Geneva | Reading time: 2 min (418 words)

[Français](#)[Español](#)

Alert Summary

This WHO Medical Product Alert refers to falsified COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccines (Recombinant)) identified in the WHO African Region, and the WHO South-East Asia Region. The falsified products were reported to WHO in July and August 2021. The genuine manufacturer of COVISHIELD (Serum Institute of India Pvt. Ltd.) has confirmed that the products listed in this alert are falsified. These falsified products have been reported at the patient level in Uganda and India.

Genuine COVISHIELD vaccine is indicated for active immunisation of individuals 18 years or older for the prevention of coronavirus disease caused by the SARS-CoV-2 virus. The use of genuine COVID-19 vaccines should be in accordance with official guidance from national regulatory authorities.

Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on

vulnerable populations and health systems. It is important to detect and remove these falsified products from circulation to prevent harm to patients.

The products identified in this alert are confirmed as falsified on the basis that they deliberately/fraudulently misrepresent their identity, composition or source:

- Batch 4121Z040 - the expiry date (10.08.2021) on this product is falsified
- COVISHIELD 2ml - the genuine manufacturer does not produce COVISHIELD in 2ml (4 doses).

Table 1: Products subject of WHO Medical Product Alert N°5/2021

Product name	COVISHIELD, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)	
Stated manufacturer	Serum Institute of India Pvt. Ltd.	
Stated dose	5ml (10 doses)	2ml (4 doses)
Batch	4121Z040	Not stated
Mfg. date	Not stated	Not stated
Exp. date	10.08.2021	Not stated
Packaging language	English	English
Identified in	Uganda	India

Advice to regulatory authorities and the public

WHO requests increased vigilance within the supply chains of countries and regions likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centers, wholesalers, distributors, pharmacies, and any other suppliers of medical products.

All medical products must be obtained from authorized/licensed suppliers. The products' authenticity and physical condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.

If you are in possession of the above products, please do not use them.

If you have used these products, or you suffered an adverse reaction/event having used these products, you are advised to seek immediate medical advice from a qualified healthcare professional and to report the incident to the National Regulatory Authorities/National

Pharmacovigilance Centre.

National regulatory / health authorities are advised to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact rapidalert@who.int

Table 2: Photographs of products subject of WHO Medical Product Alert N°5/2021





**WHO Global Surveillance and Monitoring System
for Substandard and Falsified Medical Products**

For more information, please visit our [website](#)

Email: rapidalert@who.int

Subscribe to our newsletters →

